India-US Trade Deal: Secure Terms Harder to Reverse

Source: Original editorial ↗ The Indian Express

The Lift Line

“India would, in effect, be trading permanent concessions for a temporary advantage, an exchange few governments would accept in any other setting.”

Why This Editorial Matters for Your Exam

Soumya Bhowmick of the Observer Research Foundation writes in The Indian Express of 5 October 2026 on the stalled India-US trade deal. He testified before the US-China Economic and Security Review Commission in February, ten days after the two governments unveiled the framework for an interim deal. A week after the US State Department said the deal was “90 per cent-plus there”, the US Trade Representative said he sees nothing imminent. The column is a precise guide to how shifting US tariff law affects India’s negotiating strategy, a live GS2 and GS3 theme. For the earlier sequence, see our editorial note on US tariffs and coercive diplomacy.

GS Paper 2: Bilateral agreements involving India; effect of policies of developed countries on India’s interests. GS Paper 3: Effects of liberalisation; external sector.

Background and Context

How the legal basis of US tariffs on India has shifted.

Date	Rate or action	Legal basis
August 2025	Tariffs on India climb towards 50%; a negotiating round in New Delhi called off	Executive action
Early February 2026	Interim framework and joint statement: tariff to fall from 50% to 18%; India to cut duties on US industrial goods and buy more	Interim framework
20 February 2026	US Supreme Court holds the emergency-law tariffs unlawful	IEEPA (International Emergency Economic Powers Act of 1977)
24 February 2026	Temporary global tariff on most imports	Section 122, Trade Act of 1974 (150-day limit)
24 July 2026	New tariffs based on how well each country keeps forced-labour goods out; India 10% (proposed 12.5%)	Section 301, Trade Act of 1974

What else is pending. A US investigation into “structural excess capacity”, opened in March, covers 16 economies including India and Vietnam, with a statutory deadline of March 2027. Generic medicines are exempt from new pharma duties for now, but the exemption is under review by April 2027, and the US President has announced duties on imported generics from 2028.

The Analysis

1. Confusion is the costliest tariff. The writer told the Commission that unpredictability, not any rate on paper, was the biggest cost in the relationship. Days later the IEEPA ruling made confusion “the operating condition”.

2. Three stalls, one story. Twenty months after talks began, the deal has stalled for a third time: in August 2025, in February 2026 and now. The two sides have moved closer on text while the payoff from signing keeps shifting.

3. The February gain has shrunk. The 18 per cent lost its legal basis within weeks. India’s 10 per cent under the July regime, helped by its own ban on forced-labour imports, is low, but Vietnam pays only slightly more and several countries pay the same.

4. Why a tariff edge is weak. It can be lost three ways: Washington sets relative rates and could close the gap with a US-Vietnam deal; the baseline can be reset by the excess-capacity probe or sector duties; and India’s concessions are durable while the US rate is an administrative decision.

5. What to ask for instead. A tariff ceiling for the deal’s life; treatment no less favourable than competitors; prior notice and consultation before any new tariff; sector exemptions written in, starting with pharmaceuticals (some Indian speciality medicines already enter duty-free under the new pharma tariffs); and Indian tariff cuts and purchases phased and tied to US compliance.

6. Why now. In eight months Washington has used three different laws for its tariffs. The question is no longer how low the tariff is, but how long the terms can be relied on.

Data and Institutions Vault

Prelims-grade facts:

US trade law:

• International Emergency Economic Powers Act of 1977 (IEEPA): the US Supreme Court held on 20 February 2026 that it did not authorise the tariffs.
• Section 122, Trade Act of 1974: temporary surcharge for balance-of-payments reasons, up to 150 days.
• Section 301, Trade Act of 1974: action against unfair foreign practices; basis of the July 2026 forced-labour tariffs (India 10%).

The deal:

• Joint statement of February 2026: 50% to 18% (overtaken by the ruling).
• Excess-capacity probe: 16 economies, deadline March 2027.
• Generics exemption under review by April 2027.

Institutions:

• US-China Economic and Security Review Commission: a congressional advisory body.
• USTR: Office of the United States Trade Representative.

⚠️ Watch the trap: Section 122 of the Trade Act, 1974 is time-limited to 150 days unless Congress extends it; Section 301 has no such limit. The switch in July followed from that limit.

The Debate

For the writer’s view. A tariff advantage set by executive decision can vanish overnight, while India’s tariff cuts and purchase commitments would be hard to undo; binding terms correct that asymmetry.

The other side. Washington rarely binds itself this way and may refuse, so holding out risks losing market share to rivals that sign; a limited early deal can still help exporters; and India’s own tariffs and standards are part of the friction.

The balanced verdict. Seek durability where it matters most, a ceiling and a pharma carve-out, phase India’s concessions to US compliance, and reduce dependence on any one market through other trade agreements.

How to Think About This

Compare the durability of what each side gives. In any trade deal, list each side’s concessions and ask how easily each can be withdrawn. An exchange of permanent concessions for revocable benefits is a bad bargain, whatever the headline rates. That lens works for FTAs, investment treaties and climate deals alike.

Diagram-in-Words

Takeaway Box

• Thesis: seek durable terms, not a fragile tariff gap.
• Timeline: 50% (Aug 2025), 18% promised (Feb 2026), IEEPA tariffs struck down (20 Feb), Section 122, then Section 301 at 10% (24 July).
• Risks: Vietnam deal, excess-capacity probe (March 2027), generics review (April 2027).
• Asks: ceiling, non-discrimination, notice and consultation, pharma carve-out, phased concessions.

Sources: The Indian Express, Office of the US Trade Representative, Ministry of Commerce and Industry

Source: India-US Trade Deal: Secure Terms Harder to Reverse — Ujiyari.com | Free UPSC & State PCS Editorial Analysis

Key Arguments at a Glance

Soumya Bhowmick of the Observer Research Foundation argues that India’s aim of a clear tariff advantage over rivals is a weak foundation because, under the current US system, that edge can be lost overnight; India should spend its bargaining power on terms that are harder to reverse.

✓ Supporting

• The February 2026 joint statement was to cut US tariffs on Indian goods from 50 to 18 per cent, but within weeks the US Supreme Court struck down the emergency-law tariffs on which it rested; a temporary global tariff followed, then July’s forced-labour-linked tariffs, with India at 10 per cent.
• The edge is relative and Washington decides it: India’s proposed 12.5 per cent was cut to 10, Vietnam pays only slightly more, and a US-Vietnam deal could erase India’s margin.
• The baseline can shift: a “structural excess capacity” investigation opened in March covers 16 economies with a March 2027 deadline, and the exemption for generic medicines from new pharma duties is under review by April 2027, with duties on generics announced from 2028.
• India’s concessions (industrial tariff cuts, some farm openings, purchase commitments) would be long-lasting and politically hard to reverse, while what it gets is an administrative rate Washington can change alone.

⚠ Counter

A wider view, not in the column: the US is unlikely to bind itself to a tariff ceiling it denies other partners, so pressing for one may stall talks further while competitors sign; a smaller, early deal could still lock in market share; and India’s own tariffs and non-tariff barriers are part of why talks are hard.

→ Way Forward

The writer asks India to seek a tariff ceiling for the deal’s life, treatment no less favourable than competitors, prior notice and consultation before any new tariff, written sector carve-outs starting with pharmaceuticals, and phased Indian concessions tied to US compliance. Ujiyari’s synthesis: pair that with export diversification through the EU, UK, EFTA and other agreements so that no single market sets India’s terms.